Innovation

The University of Pittsburgh Alzheimer Disease Research Center (ADRC) has joined the National Institute of Health for a major clinical trial, the gold standard for medical research, that may determine if omega-3 fatty acids—long believed to be beneficial to good health—can slow the progression of Alzheimer’s disease.

The study is based on findings that omega-3 fatty acids, found in the oil of some fish, algae and human breast milk, also may benefit the brain by lowering the risk of Alzheimer’s. Researchers will test whether docosahexaenoic acid (DHA), an omega-3 fatty acid, slows the progression of both cognitive and functional decline in people with mild to moderate Alzheimer’s.

“Evidence to date in various research studies that have examined the effect of omega-3 fatty acids on Alzheimer’s disease merits further evaluation in a rigorous clinical trial,” said Dr. Steven DeKosky, professor and chair of neurology at the University of Pittsburgh School of Medicine. “Our hope is that we may find that DHA plays a role in slowing the progression of this destructive disease. Study volunteers will be critical to helping us find out if DHA can make an impact on the disease process.”

Pitt researchers are looking for 15 participant volunteers who will be monitored over an 18-month period. To learn how to participate in the study, contact Mary Ann Oakley at 412-692-2700 or the NIA’s Alzheimer’s Disease Education and Referral Center at 1-800-438-4380.